Publications

  1. Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M. A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clin Proc Innov Qual Outcomes. 2019 Mar; 3 (1):14-22 Epub 2019 Feb 26
    View PubMed
  2. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb; 32 (2):267-276 Epub 2018 Nov 17
    View PubMed
  3. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019 Jan 3; 73 (1):22-35.e6 Epub 2018 Dec 06
    View PubMed
  4. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019; 6:49-69 Epub 2019 Feb 05
    View PubMed
  5. Riaz IB, Wang L, Kohli M. Liquid biopsy approach in the management of prostate cancer. Transl Res. 2018 Nov; 201:60-70 Epub 2018 May 31
    View PubMed
  6. Smith L, Kohli M, Smith AM. Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration. J Am Chem Soc. 2018 Oct 24; 140 (42):13904-13912 Epub 2018 Oct 12
    View PubMed
  7. Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H. TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clin Cancer Res. 2018 Sep 15; 24 (18):4551-4565 Epub 2018 May 29
    View PubMed
  8. Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):431-437 Epub 2018 June 01
    View PubMed
  9. Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):411-418 Epub 2018 June 01
    View PubMed
  10. Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacol Ther. 2018 Jul; 104 (1):201-210 Epub 2017 Nov 22
    View PubMed
  11. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 Jun; 73 (6):847-855 Epub 2018 Feb 21
    View PubMed
  12. Zhang P, Xia JH, Zhu J, Gao P, Tian YJ, Du M, Guo YC, Suleman S, Zhang Q, Kohli M, Tillmans LS, Thibodeau SN, French AJ, Cerhan JR, Wang LD, Wei GH, Wang L. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun. 2018 May 22; 9 (1):2022
    View PubMed
  13. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10; 36 (11):1080-1087 Epub 2018 Jan 31
    View PubMed
  14. He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res. 2018 Feb 28; 46 (4):1895-1911
    View PubMed
  15. Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Feb 15; 24 (4):834-846 Epub 2017 Nov 22
    View PubMed
  16. Sanhueza C, Kohli M. Clinical and Novel Biomarkers in the Management of Prostate Cancer. Curr Treat Options Oncol. 2018 Feb 8; 19 (2):8 Epub 2018 Feb 08
    View PubMed
  17. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 1; 29 (2):352-360
    View PubMed
  18. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ, ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb 1; 36 (4):376-382 Epub 2017 Dec 20
    View PubMed
  19. Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int J Mol Sci. 2017 Nov 3; 18 (11) Epub 2017 Nov 03
    View PubMed
  20. Giridhar KV, Kohli M. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clin Proc. 2017 Oct; 92 (10):1564-1582
    View PubMed
  21. Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017 Sep 8; 8 (38):63703-63714 Epub 2017 July 22
    View PubMed
  22. Kohli M, Ho Y, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug 15; 23 (16):4704-4715 Epub 2017 May 04
    View PubMed
  23. Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L. Low hypoxia inducible factor-1alpha (HIF-1alpha) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017 Aug; 29 (4):374-378
    View PubMed
  24. Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int. 2017 Mar; 119 (3):489-495 Epub 2016 Aug 06
    View PubMed
  25. Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016 Nov 10; 15 (1):70
    View PubMed
  26. Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016 Oct; 17 (10):1435-1444 Epub 2016 Aug 27
    View PubMed
  27. Shenoy N, Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016 Oct-Dec; 32 (4):257-261
    View PubMed
  28. Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci. 2016 Jul 9; 17 (7) Epub 2016 July 09
    View PubMed
  29. Zhao J, Zhao Y, Zhang J, Karnes RJ, Kohli M, Wang G, Wang G, Huang H. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 2016 Jun 21; 7 (25):38551-38565
    View PubMed
  30. Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016 Jun 14; 7 (24):35818-35831
    View PubMed
  31. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387 (10032):2008-16 Epub 2016 Mar 09
    View PubMed
  32. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 1; 34 (13):1500-9 Epub 2016 Feb 29
    View PubMed
  33. Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep. 2016 Apr 19; 15 (3):599-610 Epub 2016 Apr 07
    View PubMed
  34. Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016 Apr 15; 6 (4):e010332
    View PubMed
  35. Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JP. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. 2016 Feb 3; 17:58 Epub 2016 Feb 03
    View PubMed
  36. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016 Jan 20; 6:19413
    View PubMed
  37. Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate. 2016 Jan; 76: (1)48-57.
    View PubMed
  38. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373 (8):737-46 Epub 2015 Aug 05
    View PubMed
  39. Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D, White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz M, Singal PK, Mulvagh S, Jassal DS. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Aug 15; 309 (4):H692-701 Epub 2015 June 19
    View PubMed
  40. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun 30; 6 (18):16411-21
    View PubMed
  41. Thanarajasingam G, Milone M, Kohli M. Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep. 2015 May 4; 2015 Epub 2015 May 04
    View PubMed
  42. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67 (1):33-41 Epub 2014 Aug 14
    View PubMed
  43. Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One. 2015; 10 (12):e0145176 Epub 2015 Dec 22
    View PubMed
  44. Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV. Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther. 2015; 8:1915-22 Epub 2015 July 30
    View PubMed
  45. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep; 89 (9):1287-306
    View PubMed
  46. Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug; 192 (2):357-63 Epub 2014 Mar 12
    View PubMed
  47. Vaa B, Kohli M, Price KA, Swetz KM. Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Rep. 2014 Jun 11; 2014 Epub 2014 June 11
    View PubMed
  48. Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May; 13 (5):1067-77 Epub 2014 Mar 27
    View PubMed
  49. Loprinzi PD, Kohli M. Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national U.S. sample. Journal of Physical Activity and Health. 2014; 11(8):1587-92.
    View PubMed
  50. Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014; 120(5):692-701.
    View PubMed
  51. Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 2014; 5(3):824-40.
    View PubMed
  52. Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L. ERNA: A graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing. BMC Genomics. 2014; 15(1):176.
    View PubMed
  53. Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013 Nov 26; 7(11):9518-25.
    View PubMed
  54. Qin R, Kohli M. Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Per Med. 2013 Nov; 10 (8):859-869
    View PubMed
  55. Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc. 2013 Jan; 88(1):11-21.
    View PubMed
  56. Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors. 2013; 5 (3):e29 Epub 2013 July 05
    View PubMed
  57. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013; 14:319. Epub 2013 May 10.
    View PubMed
  58. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens health. 2012 Sep 1; 9(3):182-9.
    View PubMed
  59. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87 (6):540-7
    View PubMed
  60. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87 (3):240-6
    View PubMed
  61. Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Mar; 14 (2):193-7 Epub 2012 Jan 30
    View PubMed
  62. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019 Epub 2012 Feb 22
    View PubMed
  63. Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012:781459 Epub 2012 Aug 22
    View PubMed
  64. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13 (3):365-77 Epub 2011 May 11
    View PubMed
  65. Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr; 9 (4):335-8
    View PubMed
  66. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest. 2011 Jan; 29 (1):62-7
    View PubMed
  67. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010 Jan; 85 (1):77-86
    View PubMed
  68. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31.
    View PubMed
  69. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7 (2):101-8
    View PubMed
  70. Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4.
    View PubMed
  71. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6.
    View PubMed
  72. Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U. Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7.
    View PubMed
  73. Kohli M, Schaefer R. Management of solitary palatal metastasis from renal cell carcinoma. Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396.
    View PubMed
  74. Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M. Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800.
    View PubMed
  75. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
    View PubMed
  76. Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58.
    View PubMed
  77. Kaushal V, Kohli M, Richard D, Chiles W, Mukunyadzi P. Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21.
  78. Challagundla S, Gokden M, Viswamitra S, Kohli M. Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer.2005 Sep;4:(2):134-7.
    View PubMed
  79. Alikhan MA, Spencer HJ, Kohli M. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol.2005 Sep 1;23:(25):6267-8.
  80. Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M. Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol.2005 May;3:(5):425-7.
    View PubMed
  81. Kaushal V, Dennis R, Mukunyadzi P, Siegel E, Johnson D, Kohli M. Stage specific expression of VEGF A and D in prostate cancer. Clin Cancer Res. 2005; 11:1-10.
  82. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20.
    View PubMed
  83. Kohli M, Mukunyadzi P, Dennis RA, Johnson DE, Kaushal V. COX-2: an inconsistent therapeutic target in prostate cancer. Uro Oncology. 2004 Sep/Dec; 4(3/4):113-8.
  84. Kohli M, Zent C, Hutchins LF, Safar M, Dotson, P, Mehta P. The academic hematology-oncology firm: a model for postgraduate cancer education. J Cancer Educ. 2004 Spr; 19(1):45-9.
    View PubMed
  85. Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445.
    View PubMed
  86. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003 Jun; 29(3):301-8.
    View PubMed
  87. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003 Apr; 61(4):765-9.
    View PubMed
  88. Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58.
    View PubMed
  89. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3.
    View PubMed
  90. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5.
    View PubMed
  91. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71.
    View PubMed